Principal Investigator
Jose Lutzky
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20230966
Clinical Trial Summary
IDE196 (Darovasertib) In Combination With Crizotinib Versus Investigators Choice Of Treatment As First-Line Therapy In HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)
Phase
Phase II/III
Funding Agency/Sponsor
Industrial
Disease
Cutaneous Malignancies
Contact Information
Phone Number
305-243-2647